Company research / TOVX
Theriva Biologics, Inc. (TOVX)
- Sector Manufacturing
- Incorporated NV
- Fiscal year ends Dec 31
For the year ended 2011-12-31, Theriva Biologics, Inc. reported revenue of $0. Revenue fell 100.0% from the prior annual period.
Key ratios (year ended 2011-12-31)
-100.0%
Revenue growth (YoY)
Beyond the statements
Follow the company.
Explore new filings, reported insider transactions and company relationships.
Price chart
Annual financials
| Period ended | 2025-12-31 | 2024-12-31 | 2024-08-26 | 2024-08-25 | 2023-12-31 | 2022-12-31 | 2022-09-30 | 2022-07-25 | 2022-07-24 | 2022-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -$24.05M | -$26.35M | — | — | -$21.43M | -$21.58M | — | — | — | — |
| Net Income | -$23.74M | -$25.65M | — | — | -$18.35M | -$19.68M | — | — | — | — |
| EPS (Diluted) | $-2.08 | $-19.03 | — | — | $-28.48 | $-1.31 | — | — | — | — |
| Total Assets | $38.24M | $35.35M | — | — | $55.22M | $71.86M | $77.11M | — | — | $80.64M |
| Total Liabilities | $22.86M | $16.29M | — | — | $15.52M | $17.30M | $17.99M | — | — | $18.42M |
| Shareholders' Equity | $15.38M | $19.07M | — | — | $36.96M | $51.83M | $56.39M | — | — | $62.22M |
| Cash & Equivalents | $13.06M | $11.61M | — | — | $23.18M | $41.79M | $50.49M | — | — | $52.27M |
| Operating Cash Flow | -$16.67M | -$16.94M | — | — | -$19.00M | -$19.08M | — | — | — | — |
| Capital Expenditures | $35.0K | $1.0K | — | — | $202.0K | $116.0K | — | — | — | — |
| Shares Outstanding | 35.69M | 2.78M | 1.01M | 25.13M | 686.2K | 15.12M | 15.84M | 15.84M | 158.44M | 15.84M |
| Weighted Average Diluted Shares | 12.14M | 1.35M | — | — | 644.3K | 15.33M | — | — | — | — |
| EPS (Basic) | $-2.08 | $-19.03 | — | — | $-28.48 | $-1.31 | — | — | — | — |